Short answer
Tectonic Therapeutic, Inc. (TECX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$22M
- −11.5% YoY · +11.7% QoQ
- EPS (diluted)
- −$1.18
- −10.3% YoY · +11.9% QoQ
Source: XBRL data from the Tectonic Therapeutic, Inc. (TECX) Q2 2026 10-Q on SEC EDGAR. USD.
Tectonic Therapeutic, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Operating expenses $24.2M, up 8% YoY; operating loss $24.2M vs $22.3M
- TX45 R&D $7.0M, up 25%; TX2100 R&D $2.8M, down 44%
- Cash $227.1M at June 30; six-month operating cash outflow $39.9M vs $27.8M
- ATM generated $11.7M net proceeds; APEX topline results expected early Q1 2027
Risk Factors
- Net loss $22.3 million for three months ended June 30, 2026, versus $20.0 million in 2025
- Cash and equivalents $227.1 million, expected to fund planned operations for at least 12 months
- Additional capital needs tied to Phase 2 TX45 trials and Phase 1a TX2100 development
- Clinical-trial risk heightened by TX45 Phase 2 and TX2100 Phase 1a status
- Regulatory risk from potential FDA disagreement over trial design, endpoints, or clinical data interpretation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tectonic Therapeutic, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.